Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results

o adequate exercise stress. Ranolazine is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

--Tables to follow--



(In Thousands, Except Per Share Amounts)


Three months ended Six months ended

June 30, June 30,

2008 2007 2008 2007


Product sales, net $25,

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
(Date:10/9/2015)... Oct. 9, 2015  Pulmatrix, Inc., (NASDAQ: PULM ) ... investor conferences. th Annual BIO Investor ... (2:00 pm EDT). --> th Annual ... am PDT (2:00 pm EDT). --> Pulmatrix ... Growth Stock Conference on Thursday, October 15, 2015 at 8:30 ...
(Date:10/9/2015)... Michigan (PRWEB) , ... October 09, 2015 , ... ... around us. However, the current methods of separating those cells from their surroundings ... and damaging to the cells. , To address this, Ann Arbor-based startup ...
(Date:10/9/2015)... ... October 09, 2015 , ... Leading microbial genomics startup ... to better understand the relationship between weight management and the microbiome. The study uses ... from participants using an iPhone app. , The uBiome app is available as a ...
(Date:10/8/2015)... UK (PRWEB) , ... October 08, 2015 , ... Researchers ... literally see inside the living brain, providing a new tool to study how diseases ... is reported by Woo June Choi and Ruikang Wang of the UW Department of ...
Breaking Biology Technology:
... 22 The Delaware Court of,Chancery today issued its ... a,stockholder of Cryo-Cell International Inc. (OTC Bulletin Board: CCEL),challenging ... held,on July 16, 2007. The court ordered the Company ... stockholders meeting to be held on March 4, 2008,commencing ...
... FOSRENOL(R), SARATOGA SPRINGS, N.Y., Jan. 22 Palio, ... to announce that Shire,Pharmaceuticals (LSE: SHP, Nasdaq: SHPGY, TSX: ... the professional advertising and promotion for,Shire,s FOSRENOL, which is ... excited to put our team,s experience and insight to ...
... 22 A free white paper for clinical,laboratory ... from Spiral Biotech, Inc. at, ., ... clinicians,are faced with the ongoing challenge of quickly ... of pathogens. As a result, clinical laboratories,face growing ...
Cached Biology Technology:
(Date:10/9/2015)... , Oct. 09 2015 ... addition of the "Samsung Galaxy S6 ... report to their offering. --> ... the "Samsung Galaxy S6 Fingerprint Sensor ... their offering. --> Research and ...
(Date:10/8/2015)... , Oct. 8, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, announced today that it will report ... 2016 on Thursday, October 22, 2015, after the ... corresponding conference call for analysts and investors at ... management may discuss forward-looking information.    ...
(Date:10/8/2015)... , 8. Oktober 2015 ... global tätiges Unternehmen des Bereiches Tracking, hat ... mit der Gefängnisbehörde Virginias (Department of Corrections ... elektronische Überwachungsdienste für alle Strafen geliefert werden, ... Cassell , Präsident für den Amerikanischen Kontinent ...
Breaking Biology News(10 mins):
... CORVALLIS, Ore. The National Science Foundation has notified Oregon ... a project to finalize the design and coordinate the construction ... bolster the marine science research capabilities of the United States. ... the design phase of the project and if funds ...
... Ecology is rife with predation, competition, and other ... determine the course life on Earth. Organisms sometimes ... Stress Gradient Hypothesis, their "positive interactions" become measurably ... such as drought. Ecologists have argued about the ...
... Mass. , Jan. 30, 2013 /PRNewswire-iReach/ -- BlueMetal Architects, ... it has appointed former Microsoft Health Solutions Group Director and ... to be Vice President of Health & Life Sciences.  Mr. ... Boston office and will be responsible ...
Cached Biology News:
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Freezing-point Osmometer for 30 L samples, featuring 24-position turntable. Provides up to 30 minutes of ... software for statistical analysis and record keeping. RS-232 port. ... ... ...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
Biology Products: